Altiscreen receives CHF 150,000 from Venture Kick
The Jura-based medtech startup Altiscreen has obtained CHF 150,000 from Venture Kick to build a portable drug-testing solution that delivers clear results in just three minutes. Its device is designed to support roadside checks, workplace screening, and mobile healthcare teams that need reliable information on the spot.
Every day, delayed or unreliable field drug tests put communities, first responders, and workers at risk. Current solutions often require laboratory analysis, involve long processing times, or lack accuracy in real-world environments. Whether at roadside controls, workplaces, or public events, decision-makers increasingly need rapid, trustworthy tools to assess situations and respond safely.
The medtech startup Altiscreen develops portable testing devices that provide fast and accurate detection of multiple substances using oral fluid, urine, or trace samples. Results are available in around three minutes, enabling immediate decision-making and significantly reducing the need for laboratory follow-up. The technology is suited for a wide range of applications, including healthcare, workplace safety, law enforcement, and event management, where dependable on-the-spot screening is essential.
Combining a fast-growing pipeline with a scalable business model, Altiscreen aims to deploy several thousand drug-screening devices per year worldwide in the coming years, helping improve safety on the road and in the workplace. With drug consumption rising globally, the startup has strong potential and a clear strategic plan for the years ahead.
The CHF 150,000 from Venture Kick will be allocated mainly to sales and marketing activities, including customer visits, product demonstrations, and outbound initiatives. Part of the funding will also support R&D and the expansion of Altiscreen’s production capacity.
Altiscreen was founded in 2024 by Dr. Leonard Dumea, who brings experience in developing practical, field-ready diagnostic technologies. Focused on reliability, portability, and ease of use, the team aims to make rapid drug screening more accessible across multiple sectors. “Venture Kick was crucial in Altiscreen’s development. We found the right mix of experience, know-how, and guidance to advance our venture,” said CEO and co-founder Leonard Dumea. “We are pleased with the progress made over the past months, which is partly due to Venture Kick’s support. We thank the Venture Kick team and jury members for their trust and look forward to meeting them in our next equity round.”
➡️ Source: Venture Kick | 📸 DR. Altiscreen’s co-founders: CEO Leonard Dumea and CFO Florian Saner